New Treatment Options for Advanced Prostate Cancer

More agents have gained FDA approval in advanced prostate cancer during the past three years than were approved in the previous two decades, mentions moderator Raoul S. Concepcion, MD. Altogether, since 2010, sipuleucel-T, abiraterone acetate, enzalutamide, cabazitaxel, and radium-223 have all gained approval to treat metastatic castration-resistant prostate cancer (mCRPC). In this segment, panelists describe their experience with some of the agents approved since 2010.

For more from this discussion, visit http://www.onclive.com/peer-exchange/...

• #education
• #cancer
• #oncology
• #prostate_cancer_disease_or_medical_condition
• #medicine_field_of_study
• #abiraterone
• #enzalutamide
• #denosumab
• #radium_223
• #provenge